134 related articles for article (PubMed ID: 30703478)
1. Development of conformational antibodies targeting Cripto-1 with neutralizing effects in vitro.
Focà G; Iaccarino E; Focà A; Sanguigno L; Untiveros G; Cuevas-Nunez M; Strizzi L; Leonardi A; Ruvo M; Sandomenico A
Biochimie; 2019 Mar; 158():246-256. PubMed ID: 30703478
[TBL] [Abstract][Full Text] [Related]
2. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of small bicyclic peptide inhibitors of Cripto-1 activity.
Iaccarino E; Calvanese L; Untiveros G; Falcigno L; D'Auria G; Latino D; Sivaccumar JP; Strizzi L; Ruvo M; Sandomenico A
Biochem J; 2020 Apr; 477(8):1391-1407. PubMed ID: 32215602
[TBL] [Abstract][Full Text] [Related]
4. Structural insights into the interaction between the Cripto CFC domain and the ALK4 receptor.
Calvanese L; Saporito A; Oliva R; D' Auria G; Pedone C; Paolillo L; Ruvo M; Marasco D; Falcigno L
J Pept Sci; 2009 Mar; 15(3):175-83. PubMed ID: 19035567
[TBL] [Abstract][Full Text] [Related]
5. The CRIPTO/FRL-1/CRYPTIC (CFC) domain of human Cripto. Functional and structural insights through disulfide structure analysis.
Foley SF; van Vlijmen HW; Boynton RE; Adkins HB; Cheung AE; Singh J; Sanicola M; Young CN; Wen D
Eur J Biochem; 2003 Sep; 270(17):3610-8. PubMed ID: 12919325
[TBL] [Abstract][Full Text] [Related]
6. Cripto monoclonal antibodies.
Hu XF; Xing PX
Drug News Perspect; 2005 Jun; 18(5):293-303. PubMed ID: 16193101
[TBL] [Abstract][Full Text] [Related]
7. New Anti-Nodal Monoclonal Antibodies Targeting the Nodal Pre-Helix Loop Involved in Cripto-1 Binding.
Focà A; Sanguigno L; Focà G; Strizzi L; Iannitti R; Palumbo R; Hendrix MJ; Leonardi A; Ruvo M; Sandomenico A
Int J Mol Sci; 2015 Sep; 16(9):21342-62. PubMed ID: 26370966
[TBL] [Abstract][Full Text] [Related]
8. Conformational features and binding affinities to Cripto, ALK7 and ALK4 of Nodal synthetic fragments.
Calvanese L; Sandomenico A; Caporale A; Focà A; Focà G; D'Auria G; Falcigno L; Ruvo M
J Pept Sci; 2015 Apr; 21(4):283-93. PubMed ID: 25588905
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and Cellular Analysis Reveals Ligand Binding Specificities, a Molecular Basis for Ligand Recognition, and Membrane Association-dependent Activities of Cripto-1 and Cryptic.
Aykul S; Parenti A; Chu KY; Reske J; Floer M; Ralston A; Martinez-Hackert E
J Biol Chem; 2017 Mar; 292(10):4138-4151. PubMed ID: 28126904
[TBL] [Abstract][Full Text] [Related]
10. A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth.
Ishii H; Zahra MH; Takayanagi A; Seno M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567764
[TBL] [Abstract][Full Text] [Related]
11. Biological function analysis of monoclonal antibodies against human granulins in vitro using U251 cells as a model.
Li Y; Li Y; Ye M; Wang D; Zhao J; Sun X; Mao Q; Xia H
Protein Expr Purif; 2017 Feb; 130():55-62. PubMed ID: 27693922
[TBL] [Abstract][Full Text] [Related]
12. Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers.
Sandomenico A; Ruvo M
Curr Med Chem; 2019; 26(11):1994-2050. PubMed ID: 30207211
[TBL] [Abstract][Full Text] [Related]
13. Cripto forms a complex with activin and type II activin receptors and can block activin signaling.
Gray PC; Harrison CA; Vale W
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5193-8. PubMed ID: 12682303
[TBL] [Abstract][Full Text] [Related]
14. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways.
Kelber JA; Panopoulos AD; Shani G; Booker EC; Belmonte JC; Vale WW; Gray PC
Oncogene; 2009 Jun; 28(24):2324-36. PubMed ID: 19421146
[TBL] [Abstract][Full Text] [Related]
15. Administration of Cripto in GRP78 overexpressed human MSCs enhances stem cell viability and angiogenesis during human MSC transplantation therapy.
Kim S; Yoon YM; Han YS; Lee JH; Hur J; Lee SH
Cell Prolif; 2018 Oct; 51(5):e12463. PubMed ID: 29722092
[TBL] [Abstract][Full Text] [Related]
16. The multifaceted role of the embryonic gene Cripto-1 in cancer, stem cells and epithelial-mesenchymal transition.
Klauzinska M; Castro NP; Rangel MC; Spike BT; Gray PC; Bertolette D; Cuttitta F; Salomon D
Semin Cancer Biol; 2014 Dec; 29():51-8. PubMed ID: 25153355
[TBL] [Abstract][Full Text] [Related]
17. Recombinant humanized Fab fragments targeting the CFC domain of human Cripto-1.
Sandomenico A; Selis F; Sivaccumar JP; Olimpieri P; Iaccarino E; Cicatiello V; Cantile M; Sanna R; Leonardi A; De Falco S; Ruvo M
Biochem Biophys Res Commun; 2024 Jan; 694():149417. PubMed ID: 38150919
[TBL] [Abstract][Full Text] [Related]
18. Exogenous Cripto-1 Suppresses Self-Renewal of Cancer Stem Cell Model.
Alam MJ; Takahashi R; Afify SM; Oo AKK; Kumon K; Nawara HM; Khayrani AC; Du J; Zahra MH; Seno A; Salomon DS; Seno M
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373174
[TBL] [Abstract][Full Text] [Related]
19. Cripto/GRP78 modulation of the TGF-β pathway in development and oncogenesis.
Gray PC; Vale W
FEBS Lett; 2012 Jul; 586(14):1836-45. PubMed ID: 22306319
[TBL] [Abstract][Full Text] [Related]
20. CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.
Zoni E; Chen L; Karkampouna S; Granchi Z; Verhoef EI; La Manna F; Kelber J; Pelger RCM; Henry MD; Snaar-Jagalska E; van Leenders GJLH; Beimers L; Kloen P; Gray PC; van der Pluijm G; Kruithof-de Julio M
Oncogene; 2017 Aug; 36(33):4739-4749. PubMed ID: 28394345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]